In line with a previous finding that KDM6A confers imatinib-resistance in CML independently of its demethylase activity [76], our study shows that catalytic-dead KDM6A mutant promotes CPT resistance in ESCC cells and xenograft model. This evidence concerns the gene KDM6A and chronic myelogenous leukemia, BCR-ABL1 positive.